摘要
背景:阿尔茨海默病(AD)是世界各国公共卫生的优先事项。与这种疾病作斗争的困难主要在于症状和原因的复杂性,对其机制的了解仍然不足,以及存在潜在的、无症状的、临床前阶段。尽管在治疗阿尔茨海默病的临床研究中不断筛选出许多药物,但由于患者反应的意外缺乏,有时还有一些重要的副作用,使其成为个性化医学的潜在应用领域。目的:提出纳米技术作为个性化药物在AD中应用的一种有价值的工具。方法:个体化医学的目的主要是基于对个体遗传学和疾病进展的了解,以及药物动力学和对现有药物的代谢反应,开发出更多的病人精确的治疗方法。优化新的、更灵敏的检测技术是获取预测和理解病人反应所需的数据池的重要工具。结果:生物传感器的研究已经为AD的核心和新的生物标志物提供了高灵敏度的例子。在治疗中,纳米粒子表面的功能化可以为生物识别或提高生物利用度增加特异性。这将允许使用较低剂量的药物,但由于当地的靶向作用,副作用较小。结论:考虑到纳米粒子作为精细药物开发的优良候选工具的优良特性,建立更好的安全评价和生产规模的标准方法将有利于纳米材料的有成效的应用。
关键词: 纳米粒子,阿尔茨海默病,精密医学,纳米技术,靶向医学,生物传感器,神经变性。
Current Medicinal Chemistry
Title:Nanotechnology in Personalized Medicine: A Promising Tool for Alzheimer’s Disease Treatment
Volume: 25 Issue: 35
关键词: 纳米粒子,阿尔茨海默病,精密医学,纳米技术,靶向医学,生物传感器,神经变性。
摘要: Background: Alzheimer’s disease (AD) is a public health priority all over the world. The difficulty of fighting the disease consists mostly in the complexity of symptoms and causes, in the still poor knowledge of its mechanisms and in the existence of a latent, asymptomatic, preclinical stage. Although many drugs are continuously screened in clinical studies for the treatment of Alzheimer’s disease, the unexpected lack of patient response and sometimes the important adverse effects make it a potential field of application for personalized medicine.
Objective: This perspective review proposes nanotechnology as a valuable tool for the application of personalized medicine to AD.
Methods: The aim of personalized medicine is the development of more patient-precise treatments based mostly on the knowledge of individual genetics as well as of disease progress, and of pharmacokinetics and metabolic response to available drugs. The optimization of new and more sensitive detection techniques is an important tool for obtaining the pool of data needed for prediction and understanding of patient response.
Results: Research in bionanosensors is already providing examples with high sensitivity for core and new biomarkers for AD. In therapy the functionalization of nanoparticle surface can add specificity for biological recognition or for improving the bioavailability. This would allow the administration of lower doses with less adverse effects due to the local targeting.
Conclusion: Taking into account the promising characteristics of nanoparticles as excellent candidate tools for precision medicine development, the establishment of better standard methods for safety assessment and production scale up would be desirable for the nanomaterial fruitful employment.
Export Options
About this article
Cite this article as:
Nanotechnology in Personalized Medicine: A Promising Tool for Alzheimer’s Disease Treatment, Current Medicinal Chemistry 2018; 25 (35) . https://dx.doi.org/10.2174/0929867324666171012112026
DOI https://dx.doi.org/10.2174/0929867324666171012112026 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Sleep, Depression and Insomnia – A Vicious Circle?
Current Psychiatry Reviews Antioxidants in Health, Disease and Aging
CNS & Neurological Disorders - Drug Targets In Vivo Bio-imaging Using Chlorotoxin-based Conjugates
Current Pharmaceutical Design Pharmacological Properties of Novel Cyclic Pentapeptides with µ-opioid Receptor Agonist Activity
Medicinal Chemistry The Role of Microbiota and Intestinal Permeability in the Pathophysiology of Autoimmune and Neuroimmune Processes with an Emphasis on Inflammatory Bowel Disease Type 1 Diabetes and Chronic Fatigue Syndrome
Current Pharmaceutical Design Hold Onto Your Hat! - Handling the Roller Coaster Emotions of the College Application Process
Adolescent Psychiatry Recent Developments in Mass Spectrometry Analysis of Phosphoproteomes
Current Proteomics MiR-22-3p Regulates Amyloid β Deposit in Mice Model of Alzheimer's Disease by Targeting Mitogen-activated Protein Kinase 14
Current Neurovascular Research Natalizumab Changes the Peripheral Profile of the Th17 Panel in MS Patients: New Mechanisms of Action
CNS & Neurological Disorders - Drug Targets Altered Functional Connectivity of the Marginal Division in Alzheimer’s Disease
Current Alzheimer Research Pyrazolines: A Biological Review
Mini-Reviews in Medicinal Chemistry The Cannabinoids Switch of Oxidative Stress: A Double-Edged Sword
Mini-Reviews in Organic Chemistry Targeting MDM2-p53 Interaction for Cancer Therapy: Are We There Yet?
Current Medicinal Chemistry Clinical Trials in Relapsing-Remitting Multiple Sclerosis /A New Proposal for Dealing with Basic Problems and Restrictions/
Reviews on Recent Clinical Trials Diversity of Human Immune System Multigene Families and its Implication in the Genetic Background of Rheumatic Diseases
Current Medicinal Chemistry An Overview on Potential Neuroprotective Compounds for Management of Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets Low-Dose Radiation Stimulates Wnt/β-Catenin Signaling, Neural Stem Cell Proliferation and Neurogenesis of the Mouse Hippocampus in vitro and in vivo
Current Alzheimer Research Electrochemical Biosensor for the Detection of Glycated Albumin
Current Alzheimer Research Follow-Up Study of Olfactory Deficits, Cognitive Functions, and Volume Loss of Medial Temporal Lobe Structures in Patients with Mild Cognitive Impairment
Current Alzheimer Research The Clinical Potential of Worms and their Products in Treating Inflammatory Diseases
Current Immunology Reviews (Discontinued)